Chemotherapy-Induced Anemia Market Size, Share & Trends Analysis Report, By Type of Anemia (Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia), By Treatment Type (RBC Transfusion, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp Injection, Epoetin Alfa Injection, and Others), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Region, Forecasts, 2024-2031

Report Id: 2511 Pages: 180 Last Updated: 18 October 2024 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Chemotherapy-Induced Anemia Market-

Chemotherapy-Induced Anemia Market-By Type of Anemia

  • Mild Anemia
  • Moderate Anemia
  • Severe Anemia
  • Life-Threatening Anemia

Chemotherapy-Induced Anemia Market seg

Chemotherapy-Induced Anemia Market-By Treatment Type

  • RBC Transfusion
  • Erythropoiesis-stimulating agents (ESAs)
  • Iron Supplementation

Chemotherapy-Induced Anemia Market-By Drug Type

  • Epogen Injection
  • Procrit Injection
  • Androxy Oral
  • Aranesp Injection
  • Epoetin Alfa Injection
  • Others

Chemotherapy-Induced Anemia Market-By End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

Chemotherapy-Induced Anemia Market-By Region

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Chemotherapy Induced Anemia Market Snapshot

Chapter 4. Global Chemotherapy Induced Anemia Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Range of Anemia Estimates & Trend Analysis

5.1. by Range of Anemia & Market Share, 2019 & 2031

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Range of Anemia:

5.2.1. Mild Anemia

5.2.2. Moderate Anemia

5.2.3. Severe Anemia

5.2.4. Life-Threatening Anemia

Chapter 6. Market Segmentation 2: by Treatment Type Estimates & Trend Analysis

6.1. by Treatment Type & Market Share, 2019 & 2031

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Treatment Type:

6.2.1. RBC Transfusion

6.2.2. Erythropoiesis-stimulating agents (ESAs)

6.2.3. Iron Supplementation

Chapter 7. Market Segmentation 3: by Drug Type Estimates & Trend Analysis

7.1. by Drug Type & Market Share, 2019 & 2031

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug Type:

7.2.1. Epogen Injection

7.2.2. Procrit Injection

7.2.3. Androxy Oral

7.2.4. Aranesp Injection

7.2.5. Epoetin Alfa Injection

7.2.6. Others

Chapter 8. Market Segmentation 4: by End-User Estimates & Trend Analysis

8.1. by End-User & Market Share, 2019 & 2031

8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-User:

8.2.1. Hospitals

8.2.2. Specialty Clinics

8.2.3. Ambulatory Surgical Centers

8.2.4. others

Chapter 9. Chemotherapy Induced Anemia Market Segmentation 5: Regional Estimates & Trend Analysis

9.1. North America

9.1.1. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031

9.1.2. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031

9.1.3. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031

9.1.4. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031

9.1.5. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

9.2. Europe

9.2.1. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031

9.2.2. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031

9.2.3. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031

9.2.4. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031

9.2.5. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

9.3. Asia Pacific

9.3.1. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031

9.3.2. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031

9.3.3. Asia-Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031

9.3.4. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031

9.3.5. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

9.4. Latin America

9.4.1. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031

9.4.2. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031

9.4.3. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031

9.4.4. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031

9.4.5. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

9.5. Middle East & Africa

9.5.1. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031

9.5.2. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031

9.5.3. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031

9.5.4. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031

9.5.5. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031

Chapter 10. Competitive Landscape

10.1. Major Mergers and Acquisitions/Strategic Alliances

10.2. Company Profiles

10.2.1. Astellas Pharma Inc.

10.2.2. Blausen Medical

10.2.3. Dr. Reddy's Laboratories Ltd.

10.2.4. Elsevier Inc.

10.2.5. F. Hoffmann-La Roche Ltd

10.2.6. FibroGen, Inc.

10.2.7. GlaxoSmithKline PLC

10.2.8. Healio

10.2.9. Johnson & Johnson

10.2.10. Karger AG

10.2.11. Novartis AG

10.2.12. Pfizer Inc.

10.2.13. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4028
Security Code field cannot be blank!

Frequently Asked Questions

Chemotherapy-Induced Anemia Market Size was valued at USD 2.4 Bn in 2023 and is predicted to reach USD 3.9 Bn by 2031

Chemotherapy-Induced Anemia Market is predicted to develop at a 6.5% CAGR during the forecast period for 2024-2031.

Blausen Medical, Dr. Reddy’s Laboratories Ltd., Elsevier Inc., F. Hoffmann-La Roche Ltd, FibroGen, Inc., GlaxoSmithKline PLC, Healio, Johnson & Johnso

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying